Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia  (a)

AbstractGeneral lipoprotein (Lp)  (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany f or secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment. Target levels for LDL-cholesterol should be modified in patients with hyperlipoproteinemia (a).
Source: Clinical Research in Cardiology Supplements - Category: Cardiology Source Type: research